SAB Biotherapeutics, Inc.

SABS Healthcare Biotechnology

SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023. In the quarter to June 2026, revenue fell 91.0%, EPS grew 74.3%, free cash flow fell 59.8% and total debt fell 5.01%, each against the same quarter a year earlier.

2.53 0.06 −2.32%
Market cap
$235.7M
P/E
0.0×
Fwd P/E
19.9×
Dividend yield
—
F-score
1/9
Altman Z
−5.52
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(21.16%) 4.80% (7.57%) (19.21%)
ROA
(18.01%) 3.93% (6.57%) (16.24%)
ROIC
(47.07%) (52.73%) (29.58%) (38.97%)
Return on Tangible Assets
(18.48%) 4.11% (8.06%) (19.72%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(3.53) (2.37) (0.99) (0.72)
Free Cash Flow
(37.59) (45.71) (53.16) (57.44)
Other line items

Show all line items

Columns are period end dates